Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adverse reactions to procainamide

D H Lawson, H Jick

    British Journal of Clinical Pharmacology
    |October 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Procainamide use in teaching hospitals led to adverse effects in 9.2% of patients, including arrhythmias and fever. Toxicity correlated with dose and hospital stay, but not patient factors like age or weight.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Detecting adverse drug reactions - a concise updateI. Cohort and case control studies.

    The International journal of risk & safety in medicine·2013
    Same author

    Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

    British journal of clinical pharmacology·2012
    Same author

    Epidemiology of lower limb fractures in general practice in the United Kingdom.

    Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention·2004
    Same author

    Postmarketing surveillance of the safety of cimetidine: 15-year mortality report.

    Pharmacoepidemiology and drug safety·2004
    Same author

    Statin use and cancer risk in the General Practice Research Database.

    British journal of cancer·2004
    Same author

    The risk of stillbirth in pregnancies before and after the onset of diabetes.

    Diabetic medicine : a journal of the British Diabetic Association·2003
    Same journal

    N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

    British journal of clinical pharmacology·2026
    Same journal

    The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

    British journal of clinical pharmacology·2026
    Same journal

    Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

    British journal of clinical pharmacology·2026
    Same journal

    UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

    British journal of clinical pharmacology·2026
    See all related articles

    Area of Science:

    • Pharmacovigilance
    • Clinical Pharmacology
    • Internal Medicine

    Background:

    • Procainamide is an antiarrhythmic drug used in treating cardiac conditions.
    • Drug surveillance programs are crucial for monitoring medication safety in clinical settings.

    Purpose of the Study:

    • To analyze the utilization and toxicity profile of procainamide in teaching hospitals.
    • To identify factors associated with procainamide-induced adverse events.

    Main Methods:

    • Analysis of data from a comprehensive drug surveillance program.
    • Inclusion of data from 488 patients across five countries' teaching hospitals.

    Main Results:

    • 9.2% of procainamide recipients experienced adverse effects, primarily arrhythmias, gastro-intestinal upset, and drug fever.

    Related Experiment Videos

  • Adverse effects were occasionally severe, but no fatalities were recorded.
  • Toxicity was linked to higher daily doses and longer hospitalization durations.

    • Conclusions:

    • Procainamide toxicity is dose- and duration-dependent.
    • Patient demographics and baseline laboratory values did not predict procainamide toxicity.
    • Close monitoring of procainamide dosage and treatment duration is essential to minimize adverse events.